Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase I/II Study of CP-4055 in Patients with Platinum Resistant Ovarian Cancer
2007-003323-20Phase 2Completed
- Sponsor
- Clavis Pharma
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacytarabine in ovarian cancer, sponsored by Clavis Pharma. Primary endpoint: Confirmed response rate (RR). Started Feb 2008; status: completed.
02
Drugs
elacytarabine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2007-003323-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003323-20.